Welcome to our dedicated page for Galecto news (Ticker: GLTO), a resource for investors and traders seeking the latest updates and insights on Galecto stock.
Galecto, Inc. (NASDAQ: GLTO) is a clinical-stage biopharmaceutical company developing novel therapies for cancer and liver diseases, with a growing focus on hematological malignancies. The GLTO news feed on Stock Titan aggregates company announcements, scientific updates and regulatory disclosures so readers can follow how Galecto’s pipeline and corporate strategy evolve over time.
Recent news emphasizes Galecto’s shift toward blood cancers, highlighted by the acquisition of Damora Therapeutics and the integration of a mutant calreticulin (mutCALR)-driven myeloproliferative neoplasm portfolio. Updates describe progress on DMR-001, an anti-mutCALR monoclonal antibody for essential thrombocythemia and myelofibrosis, and DMR-002, an additional anti-mutCALR antibody. News items also cover GB3226, a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of acute myeloid leukemia, including preclinical data presentations and plans for first-in-human studies.
Investors and followers of GLTO can use this page to track a range of developments: pipeline milestones such as planned IND submissions, preclinical and early clinical data disclosures, corporate transactions including the Damora acquisition and private placements, and leadership changes like the appointment of new executives with hematology/oncology experience. Financial result releases offer context on Galecto’s operating expenses, research and development priorities and cash runway.
This news archive is useful for anyone monitoring how Galecto executes on its strategy in hematology-oncology and liver disease, from the advancement of DMR-001 and GB3226 to the progress of GB1211 in liver cirrhosis and oncology combinations. Bookmark this GLTO news page to quickly access the latest company press releases and related updates as they are reported.
Damora Therapeutics (NASDAQ:DMRA) announced its name change from Galecto effective March 10, 2026, following completion of the acquisition of Damora and a concurrent private investment of approximately $285 million in November 2025.
The company reported approximately $535 million in cash and cash equivalents as of February 28, 2026, and gross proceeds of about $316 million from a February 2026 public offering. Damora plans IND/CTA submissions for lead program DMR-001 in mid-2026, additional IND/CTAs for DMR-002 (H2 2026) and DMR-003 (2027), and expects two clinical proof-of-concept datasets for DMR-001 beginning mid-2027. The pipeline targets mutCALR-driven ET and MF, affecting an estimated ~42,000 US patients.
Galecto (NASDAQ: GLTO) granted inducement equity awards on March 2, 2026 to four newly hired, non-executive employees, approved by its independent Compensation Committee under Nasdaq Listing Rule 5635(c)(4).
The awards are non-qualified stock options to purchase an aggregate of 153,700 shares at an exercise price of $29.58 per share, with a 10-year term and vesting of 25% after one year then monthly over 36 months.
Galecto (NASDAQ: GLTO) will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on March 9, 2026 at 10:40 a.m. ET.
According to the company, management will webcast the presentation live and make an archived replay available for 30 days under the Investor Calendar on the company website.
Galecto (NASDAQ: GLTO) closed an underwritten public offering of 16,644,737 common shares at $19.00 per share, including full exercise of the underwriters’ option for 2,171,052 additional shares. Gross proceeds were approximately $316.3 million before underwriting discounts, commissions and offering expenses.
Jefferies, Leerink Partners, Evercore ISI and Guggenheim Securities acted as joint book-running managers. The offering was made from an effective shelf registration dated February 10, 2026, and final prospectus documents were filed with the SEC.
Galecto (NASDAQ: GLTO) priced an underwritten public offering of 14,473,685 common shares at $19.00 per share, with gross proceeds expected to be approximately $275 million before fees and expenses. The underwriters have a 30-day option to purchase an additional 2,171,052 shares. The offering is expected to close on or about February 12, 2026, subject to customary closing conditions, and is being conducted from an automatically effective shelf registration.
Galecto (NASDAQ: GLTO) announced a proposed underwritten public offering of common stock and Series C non-voting convertible preferred stock on February 10, 2026. Each Series C preferred share is convertible into 1,000 common shares, subject to beneficial ownership conversion limits.
The company said proceeds are intended to fund preclinical studies, clinical trials, manufacturing for antibody programs, additional R&D, working capital, and general corporate purposes. Underwriters have a 30-day option to purchase additional common shares; the offering is subject to market and other conditions.
Galecto (NASDAQ: GLTO) outlined 2026 strategic priorities after acquiring Damora and expanding leadership. Key clinical milestones include an IND submission for DMR-001 (anti-mutCALR antibody) expected mid-2026 with first-in-human subcutaneous dosing and Phase 1 proof-of-concept data anticipated in 2027. A second anti-mutCALR candidate, DMR-002, is planned for IND submission in H2 2026, and GB3226 (ENL-YEATS/FLT3 inhibitor) targets an IND in Q1 2026. Management added a new COO and CMO with deep hematology/oncology experience. Financially, the company raised $285M in a November PIPE, providing runway into 2029 to support multiple data milestones.
Galecto (NASDAQ:GLTO) announced two senior hires: Sherwin Sattarzadeh as Chief Operating Officer and Dr. Becker Hewes as Chief Medical Officer, effective January 5, 2026. The company said DMR-001, a potential best-in-class mutant calreticulin (mutCALR) monoclonal antibody, remains on track for an IND submission in mid-2026 with anticipated first-in-human subcutaneous dosing and Ph1 proof-of-concept data expected in 2027. Galecto reported a cash balance that includes a $285 million PIPE raised in November 2025 and said this funding provides runway into 2029 to support multiple data milestones. The company also disclosed inducement equity grants for both executives on January 5, 2026.
Galecto (Nasdaq: GLTO) announced an inducement equity grant approved by its board on December 15, 2025 and disclosed on December 16, 2025. The board granted non-qualified stock options to purchase 312,535 shares to one new employee under the company's 2022 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $32.00 per share and vest 25% on the first anniversary of the grant date, then an additional 1/48th each month thereafter, subject to continued employment.
Galecto (NASDAQ:GLTO) completed the acquisition of Damora Therapeutics and closed a concurrent Series C private placement raising approximately $284.9 million. The combined company says the financing provides runway into 2029 to advance Damora’s anti-mutCALR portfolio led by DMR-001, a monoclonal antibody with ~10-fold greater potency versus a reference molecule in preclinical Type 2 mutCALR models.
Key timelines: IND submission for DMR-001 expected mid-2026 and Phase 1 proof-of-concept data anticipated in 2027. Galecto also plans an IND for GB3226 in Q1 2026.